Tyris Therapeutics obtains financing support from the Digitaliza-CV program of the IVACE

Tyris Therapeutics has been awarded an aid from the IVACE for the implementation of computer tools allowing workflow automation and digitization and high throughput analysis of the knowledge obtained from research.

The Valencian Institute of Business Competitiveness (Instituto Valenciano de Competitividad Empresarial – Ivace) has selected the Valencian company Tyris Therapeutics, dedicated to the development of non-viral gene therapies, to promote the implementation of innovative solutions aimed at digitization.

The aid is intended to increase the company’s competitiveness by implementing integrated information management, data security, Business Intelligence, big data analysis applications and visualization tools. The implemented solutions are provided by a software company specialized in the scientific field, in particular biological sciences, chemoinformatics, and bioinformatics.

The automation and digitization project is part of the Digitaliza-CV program, which aims to increase the technological level of SMEs in the Valencian Community, including Tyris Therapeutics for its activity in research and experimental development in biotechnology, through the implementation of new electronic, computer and communication technologies –TEICs-.

he development of this project, thanks to the granting of IVACE’s aid, represents a great impact for Tyris Therapeutics in its research of safer and more effective gene therapies for a large number of genetic diseases.

Tyris Therapeutics obtiene una ayuda del programa Digitaliza-CV del IVACE

Tyris Therapeutics obtiene financiación de la IVACE para la implementación de herramientas informáticas que permitirán impulsar la automatización y digitalización del flujo de trabajo y análisis del conocimiento obtenido de la investigación.

El Instituto Valenciano de Competitividad Empresarial (Ivace) ha seleccionado a la empresa valenciana Tyris Therapeutics, dedicada al desarrollo de terapias génicas no virales, para fomentar la implantación de soluciones innovadoras dirigidas a la digitalización.

La ayuda está destinada a aumentar la competitividad de la empresa por la implantación de aplicaciones de gestión integrada de la información, seguridad de datos, Business Intelligence, análisis y visualización de big data. Las soluciones implementadas son proporcionadas por una empresa de software especializada en el ámbito científico, en particular ciencias biológicas, quimioinformáticas, y bioinformáticas.

El proyecto de automatización y digitalización está enmarcado en el programa Digitaliza-CV, que tiene como objetivo incrementar el nivel tecnológico de pymes de la Comunitat Valenciana, entre las que se incluye Tyris Therapeutics por su actividad en investigación y desarrollo experimental en biotecnología, mediante la implantación de nuevas tecnologías electrónicas, informáticas y de las comunicaciones –TEICs-.

El desarrollo de este proyecto gracias a la concesión de la ayuda de IVACE supone para Tyris Therapeutics un gran impacto en su investigación de terapias génicas más seguras y efectivas para un gran número de enfermedades genéticas.

About Tyris

Founded in 2020, and fully owned by Columbus Venture Partners (columbusvp.com), Tyris Therapeutics SL is a privately held, fully integrated non-viral DNA-based gene therapy company dedicated to developing life-saving medicines.

Tyris’ DNA-based medicines platform includes proprietary technology to

i) produce linear closed DNA, just containing the sequence of interest, and

ii) novel non-viral vectors which have no limitation in cargo capacity and enables re-administration of any gene therapy treatment; thus, overcoming current challenges in viral gene therapy, achieving more efficient and safer therapeutics for any genetic disease.

Its pipeline covers a diverse preclinical portfolio initially focused on dermatological indications as well as on renal, hematological and pulmonary therapeutic indications.

In addition, Tyris is also exploring new horizons from a DNA-based perspective (eg vaccines, CAR-Ts or MAbs). Headquarters and main R&D laboratories are located in Valencia (Spain).

Legal warning

This document includes only summary information and is not intended to be exhaustive. The facts, figures and opinions contained in this document, in addition to historical information, are «forward-looking statements». These statements are based on the information currently available and the best estimates and assumptions that the Company considers reasonable.

These statements involve risks and uncertainties beyond the control of the Company. Therefore, actual results may differ materially from those declared by such forward-looking statements. The Company expressly waives any obligation to revise or update any forward-looking statements, goals or estimates contained in this document to reflect any changes in the assumptions, events or circumstances on which such forward-looking statements are based, unless required by the applicable law. If you wish to unsubscribe from any Almirall Corporate communication click here.

In accordance with the General Data Protection Regulation and the applicable local regulations, we inform you that your personal data is processed by Almirall S.A. with registered address at Ronda del General Mitre,151, 08022, Barcelona (Spain), acting as Controller in line with the purposes indicated in our Privacy Policy.

For further information, you may consult https://www.almirall.com/privacy-policy or contact our Data Protection Officer at the e-mail address: dpo.global@almirall.com. PRNewswire is the Agency that licenses your personal data according to their privacy policy: https://gdpr.cision.com/gdpr.

At any time you can exercise your rights of access, rectification, deletion, objection, portability as well as the limitation of the processing of your data in the terms provided in the current regulations on Data Protection, by addressing the corresponding written request to our postal address (Ronda General Mitre, 151, 08022 Barcelona, Spain).

The request to exercise any of your rights must be accompanied by a copy of an official document that identifies you (ID, driver’s license or passport). Finally, we inform you that you can contact the Spanish Data Protection Agency and any other competent public bodies for any claim arising from the processing of your personal data.